← Who reports today · Health Care
RMD · Q4 FY2026
Archived report (Q4 FY2026). Latest deep dive →
The quarter in brief
Revenue grew 8.6% y/y to $1.46B, operating margin 30.7% vs 33.7%, net income $383M (+1.0% y/y).
Net income
$383M
up 1.0% y/y
Net revenue
$1,464M
up 8.6% y/y
Income from operations
$449M
down 1.3% y/y
Gross profit
$861M
up 5.0% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net revenue | $1,464 · +8.6% |
| Cost of sales | $552 · +6.2% |
| Amortization of acquired intangibles | $8.3 · −11.4% |
| Astral field safety notification expenses | $41.9 · vs $0 |
| Gross profit | $861 · +5.0% · 58.8% margin |
| Research and development | $106 · +22.3% |
| Selling, general, and administrative | $291 · +9.6% |
| Acquisition and portfolio review related expenses | $5.6 · +177% |
| Amortization of acquired intangibles | $10.5 · −12.0% |
| Income from operations | $449 · −1.3% · 30.7% margin |
| Interest (expense) income, net | $20.9 · +263% |
| Gain (loss) attributable to equity method investments | $2.2 · +75.9% |
| Gain (loss) on equity investments | $1 · vs −$2.5 |
| Other, net | $1.3 · vs −$1 |
| Income before income taxes | $474 · +3.5% |
| Income taxes | $90.7 · +15.8% · 19.1% effective rate |
| Net income | $383 · +1.0% · $2.64/sh · 26.2% margin |
Verdict: revenue grew 8.6% y/y to $1.46B, operating margin 30.7% vs 33.7%, net income $383M (+1.0% y/y).
Resmed announced a 10% increase in its quarterly dividend to $0.66 per share.
Source and notation
Source: ResMed press release, 8-K EX-99.1 of 08/06/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: RMD, Q4 FY2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “RMD Q4 FY2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/rmd/q4-fy2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/rmd/q4-fy2026"><img src="https://whoreportstoday.com/t/rmd/q4-fy2026/sankey.png" alt="RMD Q4 FY2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/rmd/q4-fy2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/rmd/q4-fy2026/sankey.png
<a href="https://whoreportstoday.com/t/rmd/q4-fy2026">RMD Q4 FY2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Fiscal 2026 revenue rose 10% to $5.7 billion, and free cash flow was $1.6 billion.
- Gross margin was 58.8% vs 60.8% a year earlier.
- Operating income was $449M, a 30.7% margin vs 33.7% a year earlier.
- The effective tax rate was 19.1% vs 17.1% a year earlier.
- Diluted EPS was $2.64 vs $2.58 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
RMD — a medical device and software company that makes CPAP and other devices, masks and cloud-connected tools for treating sleep apnea and chronic respiratory disease at home.
It reports two segments: Sleep and Breathing Health, and Residential Care Software, which sells business management software to out-of-hospital care providers. · Source: annual report (Form 10-K, SEC)
More reports: RVTY · Q2 2026 · SOLV · Q2 2026 · STE · Q1 FY2027 · SYK · Q3 2026 · TECH · Q4 FY2026 · TMO · Q3 2026 · UHS · Q3 2026 · UNH · Q3 2026 · VEEV · Q2 FY2027 · VRTX · Q2 2026 · all reports